Literature DB >> 12393402

Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells.

Evren Ozdemir1, Lisa S St John, Geraldine Gillespie, Sarah Rowland-Jones, Richard E Champlin, Jeffrey J Molldrem, Krishna V Komanduri.   

Abstract

Cytomegalovirus (CMV) infection causes significant morbidity and mortality in the setting of immunodeficiency, including the immune reconstitution phase following allogeneic stem cell transplantation (SCT). We assessed CMV-specific CD4(+) and CD8(+) T-cell responses in 87 HLA-A*0201-positive (A2+) and/or B*0702-positive (B7+) allogeneic stem cell transplant recipients using HLA-peptide tetramer staining and cytokine flow cytometry (CFC) to examine the association of CMV-specific immune reconstitution and CMV antigenemia following SCT. Strong CMV-specific T-cell responses recovered in most subjects (77 of 87, 88%) after SCT. Frequencies of CMV-specific CD8(+) T cells were significantly higher in those subjects who experienced early antigenemia relative to those who did not (2.2% vs 0.33%, P =.0002), as were frequencies of CMV-specific CD4(+) T cells (1.71% vs 0.75%, P =.002). Frequencies of CMV-specific CD8(+) T cells were also higher in subjects experiencing late antigenemia (2.4% vs 0.57%). When we combined tetramer staining and an assessment of cytokine production in a single assay, we found that individuals who experienced CMV antigenemia had lower tumor necrosis factor-alpha (TNF-alpha)-producing fractions of tetramer-staining CMV-specific CD8(+) T cells than subjects who did not (25% vs 65%, P =.015). Furthermore, individuals at high risk for CMV reactivation, including patients with acute graft-versus-host disease and those receiving steroids, had low fractions of cytokine-producing CMV-specific CD8(+) T cells (25% and 27%, respectively). These data suggest that the inability to control CMV reactivation following allogeneic SCT is due to the impaired function of antigen-specific CD8(+) T cells rather than an inability to recover sufficient numbers of CMV-specific T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393402     DOI: 10.1182/blood-2002-05-1387

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study.

Authors:  Francesco Marchesi; Fulvia Pimpinelli; Svitlana Gumenyuk; Daniela Renzi; Francesca Palombi; Francesco Pisani; Atelda Romano; Antonio Spadea; Elena Papa; Marco Canfora; Fabrizio Ensoli; Andrea Mengarelli
Journal:  World J Transplant       Date:  2015-09-24

2.  Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.

Authors:  Katia Perruccio; Antonella Tosti; Emanuela Burchielli; Fabiana Topini; Loredana Ruggeri; Alessandra Carotti; Marusca Capanni; Elena Urbani; Antonella Mancusi; Franco Aversa; Massimo F Martelli; Luigina Romani; Andrea Velardi
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

3.  Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.

Authors:  Krishna V Komanduri; Lisa S St John; Marcos de Lima; John McMannis; Steven Rosinski; Ian McNiece; Susan G Bryan; Indreshpal Kaur; Sean Martin; Eric D Wieder; Laura Worth; Laurence J N Cooper; Demetrios Petropoulos; Jeffrey J Molldrem; Richard E Champlin; Elizabeth J Shpall
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

Review 4.  Lymphoid reconstruction and vaccines.

Authors:  Ronald E Gress; Krishna V Komanduri; Hermann Einsele; Laurence J N Cooper
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

Review 5.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

6.  Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.

Authors:  Roy F Chemaly; Lynn El Haddad; Drew J Winston; Scott D Rowley; Kathleen M Mulane; Pranatharthi Chandrasekar; Robin K Avery; Parameswaran Hari; Karl S Peggs; Deepali Kumar; Rajneesh Nath; Per Ljungman; Sherif B Mossad; Sanjeet S Dadwal; Ted Blanchard; Dimpy P Shah; Ying Jiang; Ella Ariza-Heredia
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

8.  The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects.

Authors:  Hidekazu Itamura; Takero Shindo; Isao Tawara; Yasushi Kubota; Ryusho Kariya; Seiji Okada; Krishna V Komanduri; Shinya Kimura
Journal:  JCI Insight       Date:  2016-07-07

9.  Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation.

Authors:  Ryan M Kelly; Emily M Goren; Patricia A Taylor; Scott N Mueller; Heather E Stefanski; Mark J Osborn; Hamish S Scott; Elena A Komarova; Andrei V Gudkov; Georg A Holländer; Bruce R Blazar
Journal:  Blood       Date:  2009-12-04       Impact factor: 22.113

10.  Impact of cytomegalovirus and grafts versus host disease on the dynamics of CD57+CD28-CD8+ T cells after bone marrow transplant.

Authors:  Ana Verena Almeida Mendes; Esper Georges Kallas; Gil Benard; Cláudio Sérgio Pannuti; Reneé Menezes; Frederico Luiz Dulley; Thomas George Evans; Reinaldo Salomão; Clarisse Martins Machado
Journal:  Clinics (Sao Paulo)       Date:  2008-10       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.